The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 895-902.e4, November 2009

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

  • Tmirah Haselkorn, PhD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif
    • Corresponding Author InformationReprint requests: Tmirah Haselkorn, PhD, Genentech, Inc, 1 DNA Way, MS 58B, South San Francisco, CA 94080.
    • ,
  • James E. Fish, MD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif
    • ,
  • Stanley J. Szefler, MD

      Affiliations

    • Department of Pediatrics, National Jewish Health, Denver, Colo
    • ,
  • Dave P. Miller

      Affiliations

    • ICON Clinical Research, San Francisco, Calif
    • ,
  • Bradley E. Chipps, MD

      Affiliations

    • Capital Allergy and Respiratory Disease Center, Sacramento, Calif
    • ,
  • F. Estelle R. Simons, MD

      Affiliations

    • University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Scott T. Weiss, MD, MS

      Affiliations

    • Channing Laboratory, Harvard Medical School, Boston, Mass
    • ,
  • Sally E. Wenzel, MD

      Affiliations

    • University of Pittsburgh Asthma Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pa
    • ,
  • Larry Borish, MD

      Affiliations

    • University of Virginia Health Systems, Charlottesville, Va
    • ,
  • Eugene R. Bleecker, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • TENOR Study Group

      Affiliations

    • For a complete list of TENOR Study Group members, please contact Genentech, Inc.

Received 23 December 2008; received in revised form 6 July 2009; accepted 24 July 2009. published online 08 October 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  Supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation.

     Disclosure of potential conflict of interest: J. E. Fish is an employee of Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering and has received research support from Aerocrine, Sanofi-Aventis, Genentech, Merck & Co, and GlaxoSmithKline. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Childhood Asthma Management Program (CAMP), NHLBI Childhood Asthma Research and Education, the NIH/NHLBI Asthma Clinical Research Network, the NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium, Roos Pharmaceuticals, and GlaxoSmithKline. D. P. Miller is employed by ICON Clinical Research, which received research funding from Genentech. B. E. Chipps has received research support from Genentech, Alcon, and AstraZeneca; has provided expert witness testimony for AstraZeneca regarding Symbicort research; and is a consultant on the speakers' bureau for Sepracor, GlaxoSmithKline, AstraZeneca, Alcon, Genentech, Novartis, Schering-Plough, Aventis, MADA. F. E. R. Simons has received research support from the Canadian Institutes of Health Research. S. T. Weiss is a consultant for Genentech. S. E. Wenzel has received research support from GlaxoSmithKline and is an advisory board member for the Global Initiative for Asthma. L. Borish is a consultant for Genentech, is on the speakers' bureau for Merck, and has received research support from GlaxoSmithKline. E. R. Bleecker is a consultant for AstraZeneca, Boehringer-Ingelheim, Centocor, Genentech, GlaxoSmithKline, Novartis, Pfizer, Wyeth, and Merck and has received research support through Wake Forest University Health Sciences, Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmithKline, Novartis, Novartis, Pfizer, and Wyeth. T. Haselkorn has been a paid consultant to Genentech since December 2002.

    PII: S0091-6749(09)01144-0

    doi:10.1016/j.jaci.2009.07.035

    The Journal of Allergy and Clinical Immunology
    Volume 124, Issue 5 , Pages 895-902.e4, November 2009